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Purpose: Response to clopidogrel varies widely with nonresponse rates ranging from 4% to 
30%. A reduced function of the gene variant of the CYP2C19 has been associated with lower 
drug metabolite levels, and hence diminished platelet inhibition. Drugs that alter CYP2C19 
activity may also mimic genetic variants. The aim of the study is to investigate the cumulative 
effect of CYP2C19 gene polymorphisms and drug interactions that affects clopidogrel dosing, 
and apply it into a new clinical-pharmacogenetic algorithm that can be used by clinicians in 
optimizing clopidogrel-based treatment.
Method: Clopidogrel dose optimization was analyzed based on two main parameters that affect 
clopidogrel metabolite area under the curve: different CYP2C19 genotypes and concomitant 
drug intake. Clopidogrel adjusted dose was computed based on area under the curve ratios for 
different CYP2C19 genotypes when a drug interacting with CYP2C19 is added to clopidogrel 
treatment. A clinical-pharmacogenetic algorithm was developed based on whether clopidogrel 
shows 1) expected effect as per indication, 2) little or no effect, or 3) clinical features that 
patients experience and fit with clopidogrel adverse drug reactions.
Results: The study results show that all patients under clopidogrel treatment, whose genotypes 
are different from *1*1, and concomitantly taking other drugs metabolized by CYP2C19 require 
clopidogrel dose adjustment. To get a therapeutic effect and avoid adverse drug reactions, 
therapeutic dose of 75 mg clopidogrel, for example, should be lowered to 6 mg or increased to 
215 mg in patients with different genotypes.
Conclusion: The implementation of clopidogrel new algorithm has the potential to maximize 
the benefit of clopidogrel pharmacological therapy. Clinicians would be able to personalize 
treatment to enhance efficacy and limit toxicity.
Keywords: pharmacogenetics, genotype, genetic testing, individualized therapy
Introduction
Clopidogrel is an oral antiplatelet agent and one of the commonly prescribed 
medications worldwide in the treatment of acute coronary syndrome and in patients 
undergoing percutaneous coronary intervention to prevent recurrent atherothrombotic 
events.1 Clopidogrel is also indicated in secondary prevention of stroke in high-risk 
patients,2 as an alternative for patients who are intolerant to aspirin, with atrial fibril-
lation and cannot take warfarin.3
Response to clopidogrel varies widely with nonresponse rates ranging from 4% 
to 30% at 24 hours.4 Interindividual variability is due to the fact that clopidogrel is 
a pro-drug that requires intestinal absorption followed by enzyme biotransformation 
to yield its active metabolite, 2-oxoclopidogrel. This active thiol metabolite inhibits 
Correspondence: Yolande B saab
school of Pharmacy, Pharmaceutical 
sciences Department, lebanese 
american University, PO Box 36 F-19, 
Byblos, lebanon
Tel +961 9 547 254/262, extension 2312
Fax +961 9 547 256
email ysaab@lau.edu.lb
Journal name: Therapeutics and Clinical Risk Management
Article Designation: Original Research
Year: 2015
Volume: 11
Running head verso: Saab et al
Running head recto: Clopidogrel pharmacogenetics and drug interactions algorithm
DOI: http://dx.doi.org/10.2147/TCRM.S83293
Therapeutics and Clinical Risk Management 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1422
saab et al
adenosine diphosphate (ADP)-induced platelet aggregation 
by blocking the platelet P2Y
12
 receptor, resulting in approxi-
mately 50% reduction in ADP-mediated platelet aggregation 
after therapeutically recommended doses.5
Suggested mechanisms for this variability have included 
under-dosing, intrinsic interindividual differences resulting 
from genetic polymorphisms, and drug interactions with 
CYP2C19 substrates and inhibitors.6–8
A reduced function of the gene variant of the CYP2C19 that 
is located on chromosome 10 has been associated with lower 
clopidogrel metabolite levels, hence diminished platelet inhi-
bition, and higher rates of adverse cardiovascular events,1,9–11 
whereas an increased function of the gene variant of the 
CYP2C19 has been associated with higher clopidogrel metabo-
lite levels, and consequently an increased risk of bleeding.7
Drug interactions may mimic genetic variants. Drugs can 
alter CYP2C19 activity, and those drugs are referred to as 
either inhibitors or inducers. Drugs that inhibit CYP2C19 
activity are likely to decrease the plasma concentrations of 
the active metabolite of clopidogrel. On the other hand, some 
drugs induce (stimulate) CYP2C19, and they may increase 
the efficacy of CYP2C19 substrates like clopidogrel since 
more of the active metabolite is formed. Enzyme inducers 
tend to be “broad-spectrum”, in that they often induce several 
CYP450 isozymes. Enzyme induction interactions may be 
hard to detect clinically, since reduced drug effect may be 
interpreted as simply a lack of patient drug response.8
Comprehensive information on the effects of CYP2C19 
gene polymorphisms and drug–drug interactions on clopi-
dogrel concentrations in patients concomitantly treated with 
clopidogrel and other drugs that affect CYP2C19 function 
is unavailable. The aim of the study is to 1) investigate the 
cumulative effect of CYP2C19 gene polymorphisms and 
drug interactions that affects the plasma levels of clopidogrel 
active metabolite dosing, and 2) apply dose adjustment in a 
new algorithm that can be used in optimizing treatment and 
stratifying patients for drug response. The algorithm aims at 
providing clinicians with a guide that helps in dosing patients 
who are concomitantly treated with clopidogrel and other 
drugs metabolized by CYP2C19.
Methods
The authors confirm there is no need for ethics approval as 
this study does not deal with any ethical issues. The cumu-
lative effect of CYP2C19 gene polymorphisms and drug 
interactions that affects clopidogrel dosing was investigated 
based on the following rationale: clopidogrel is metabo-
lized by CYP2C19; CYP2C19 enzyme activity is altered in 
subjects with mutated CYP2C19 alleles who may be poor 
metabolizers, intermediate metabolizers, or ultra-extensive 
metabolizers as compared to the extensive metabolizers. 
The activity of the enzyme is also affected by drug inducers 
and inhibitors. Thus, the cumulative effect influences the 
patient’s response to clopidogrel. Drugs metabolized by 
CYP2C19 were identified and classified as enzyme inducers 
and inhibitors. CYP2C19 gene variants and their effects on 
the enzyme activity were also determined.
statistical analysis of data
The cumulative effect was analyzed based on two main 
parameters that affect clopidogrel area under the curve (AUC): 
different CYP2C19 genotypes and polypharmacy. The general 
metrics used is the ratio of altered clopidogrel AUC, where the 
alteration may be caused by either gene polymorphism or drug 
interaction, to the reference AUC measured in patients with 
no mutation or no interaction.12 The study used a software13 
to compute the AUC ratio for different CYP2C19 genotypes 
when a drug interacting with CYP2C19 is added to clopidogrel 
treatment. The adjusted dose was based on a current dose of 
75 mg, taken as an example, and is calculated as follows: 
interacting drug AUCXM with genotype (*)/AUCEM ×75 mg, 
where AUC consists of the area under the clopidogrel active 
metabolite concentration in blood or plasma over the dosing 
interval at steady state; AUCEM is the AUC of clopidogrel 
given alone in “extensive metabolizers”; AUCXM is the 
AUC of the substrate given alone in patients with any other 
phenotype (ultra-extensive metabolizer to poor metabolizer) 
as defined by the genotype of the major CYP2C19 involved 
in the substrate metabolism; and AUCXM* is the AUC of the 
substrate when given with an inhibitor or an inducer.
To obtain the adjusted dose for clopidogrel based on doses 
of 150, 300, and 600 mg, the adjusted dose of clopidogrel 75 mg 
value shall be multiplied by 2, 4, and 8, respectively.
For patients taking more than one CYP2C19 interacting 
drug along with clopidogrel, adjusted clopidogrel dose = 
(interacting drug 1 AUCXM*/AUCEM) × (interacting drug 2 
AUCXM*/AUCEM) × indicated clopidogrel dose.
Additionally, the study projected an algorithm as a clinical 
decision model for pharmacogenetic testing. The objective of 
the algorithm is to assess whether a pharmacogenetic testing is 
useful for a given patient under clopidogrel treatment. Three 
scenarios were anticipated: 1) the patient is well-controlled 
and shows expected clopidogrel effect as per indication, 2) the 
patient experiences little or no effect of clopidogrel, or 3) the 
patient presents with clinical features that fit with clopidogrel 
adverse drug reactions (ADRs). CYP2C19–drug interactions 
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were mainly considered in the algorithm decisions. Patients’ 
potential medications were explored for CYP2C19 inducers 
and/or inhibitors that interact with clopidogrel.
Results
Clopidogrel dose adjustment
Clopidogrel dose adjustment was calculated based on a 
patient whose CYP2C19 genotype is known and a drug 
metabolized by CYP2C19 and interacting with clopidogrel 
is added to the patient’s treatment. Table 1 includes a simu-
lation for clopidogrel dose of 75 mg. Table 1 differentiates 
six genotypes classified into four groups: *17*17 and *17*1 
identified as ultra-extensive metabolizers; *1*1 extensive 
metabolizers; *2-3*17 and *1*2-3 intermediate metabolizers; 
and *2-3*2-3 poor metabolizers.
The study results show that most patients under clopi-
dogrel treatment whose genotypes are different from *1*1 
and concomitantly taking other drugs metabolized by inhibit-
ing or inducing CYP2C19 most likely require clopidogrel 
dose adjustment. If concomitant drugs include but not limited 
to clarithromycin, fluconazole, fluoxetine, fluvoxamine, 
omeprazole, ticlopidine, and voriconazole, clopidogrel 
dose adjustment is required for all patients including *1*1 
genotypes. However, patients having the *17*17 genotype 
and concomitantly taking a CYP2C19 inhibitor or those 
having the *1*2-3 or *2-3*2-3 and concomitantly taking a 
CYP2C19 inducer would probably not need dose adjustment. 
For example, if a patient has the *17*17 genotype, clopi-
dogrel 75 mg as a standard therapeutic dose is required if 
clarithromycin 500–100 mg/day has been added to the patient 
treatment. To get a therapeutic effect and avoid ADRs, 
clopidogrel dose should be lowered to 6 mg and increased 
to 215 mg in patients taking ritonavir and fluvoxamine, 
respectively. Commonly, 75 mg is the indicated therapeutic 
dose for patients with *1*1 genotype; the adjusted doses 
for patients with genotypes of *17*17 and *17*1 are 45 
and 54 mg, respectively, whereas 86, 137, and 212 mg are 
the adjusted doses for patients with *2-3*17, *1*2-3, and 
*2-3*2-3 genotypes, respectively.
Clinical-pharmacogenetic algorithm
Currently, pharmacogenetic testing is performed in individual 
cases, and mostly retrospectively, for example, in patients 
who experience adverse effects or no therapeutic effect. 
Figure 1 depicts a proposed clinical decision algorithm for 
the use of pharmacogenetic testing. In brief, dosing patients 
on clopidogrel usually starts with the therapeutic doses as 
per indication. Three scenarios may apply.
Clinical situation one – supratherapeutic clopidogrel 
active metabolite
If the patient experiences clinical features that fit with 
clopidogrel ADRs, the clinician should first exclude other 
diagnoses and investigate the patient’s polypharmacy. 
If ADRs are not due to any other problem and the patient 
treatment includes only clopidogrel, a pharmacogenetic 
testing is indicated.
However, if the patient drug intake includes CYP2C19 
inducers, the latter should be discontinued and a switch to 
a drug not metabolized by CYP2C19 if available should be 
considered. If the above-mentioned clinical features persist, 
and/or no alternative to CYP2C19 inducer is available, a 
pharmacogenetic testing is indicated.
Clinical situation two – subtherapeutic clopidogrel 
active metabolite
If clopidogrel produces little or no therapeutic effect, 
the clinician should first exclude the possibility of using 
clopidogrel counterfeit and investigate the patient’s polyp-
harmacy. If the drug is genuine and the patient treatment 
includes only clopidogrel, a pharmacogenetic testing is 
indicated.
However, if the patient drug intake includes CYP2C19 
inhibitors, the latter should be discontinued and a switch 
to a drug not metabolized by CYP2C19 if available 
should be considered. If the patient lab values do not show 
improvement, and/or no alternative to CYP2C19 inhibitor is 
available, a pharmacogenetic testing is indicated.
Clinical situation three – therapeutic clopidogrel 
active metabolite
If the patient is well-controlled and shows expected clopi-
dogrel effect as per indication, clopidogrel should be con-
tinued as indicated without any change in dose.
CYP2C19 pharmacogenetic test interpretation
CYP2C19 genetic test results are provided with a genotype 
to phenotype interpretation. A normal metabolizer has two 
copies of the wild-type allele (*1*1) known as extensive 
metabolizer.11 When a variant allele replaces one or both 
wild-type alleles, this is interpreted as altered enzyme activ-
ity. Different variant alleles affecting CYP2C19 enzyme 
activity include: *17, *2, and *3. If the genotype is *17*17, 
and/or *1*17, (known as ultra-metabolizer),11 a higher drug 
metabolite level is expected, and consequently a lower 
clopidogrel dose is indicated, whereas if the genotype has 
one allele *17 or *1 in combination with *2 or *3 (which are 
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Table 1 Proposed dose adjustment of clopidogrel based on a patient whose CYP2C19 genotype is known and a drug metabolized by 
CYP2C19 and interacting with clopidogrel is added
Interacting drug Different CYP2C19 genotypes
*17*17 *1*17 *1*1 *2-3*17 *1*2-3 *2-3*2-3
amiodarone 1,200 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
azithromycin 250–500 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Benzbromarone 100 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Boceprevir 800–2400 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Bosentan 500–1,000 mg/d 25 (0.33) 30 (0.4) 44 (0.59) 52 (0.7) 100 (1.33) 210 (2.8)
Bupropion 300 mg 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Carbamazepine 200–600 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Cilcosporin 2.5–5 g/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Cimetidine 800–1,200 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Clarithromycin 500–1,000 mg/d 75 (0.99) 86 (1.15) 111 (1.48) 123 (1.64) 167 (2.23) 213 (2.84)
Diltiazem 90–270 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Diphenhydramine 150 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Dronedarone 800 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Duloxetine 120 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
efavirenz 600 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
erythromycin 1,000–2,000 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Fluconazole 100–400 mg/d 117 (1.56) 130 (1.73) 152 (2.03) 161 (2.15) 191 (2.55) 214 (2.85)
Fluoxetine 20–60 mg/d 69 (0.92) 81 (1.08) 105 (1.4) 117 (1.56) 164 (2.18) 213 (2.84)
Fluvoxamine 50–200 mg/d 200 (2.66) 203 (2.7) 206 (2.75) 208 (2.77) 212 (2.83) 215 (2.86)
Gatifloxacin 400 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
itraconazole 100–200 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Ketoconazole 200–400 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
levomepromazine 10 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Miconazole 125 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
nefazodone 400 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
noscapine 150 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Omeprazole 40–80 mg/d 68 (0.91) 80 (1.06) 104 (1.39) 116 (1.55) 163 (2.17) 213 (2.84)
Pantoprazole 80 mg/d 56 (0.75) 68 (0.9) 90 (1.2) 102 (1.36) 152 (2.02) 213 (2.84)
Paroxetine 20 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Phenytoin 300–400 mg/d 25 (0.33) 30 (0.4) 44 (0.59) 53 (0.7) 100 (1.33) 210 (2.8)
Pioglitazone 45 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Posacpnazole 200–600 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Propafenone 675 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Quinidine 50 mg 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Ranitidine 300–600 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Rifampicin 450–600 mg/d 11 (0.14) 13 (0.17) 20 (0.27) 25 (0.33) 55 (0.73) 205 (2.73)
Ritonavir 800 mg/d .14 d 6 (0.08) 7.5 (0.1) 12 (0.16) 15 (0.2) 35 (0.47) 197 (2.63)
Roxithromycin 300 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
saquinavir 3,600 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
sertraline 150 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
st John Wart 600 mg/d 29 (0.38) 35 (0.47) 51 (0.68) 86 (1.15) 110 (1.46) 210 (2.81)
sulfamethizole 600 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
sulfaphenazole 1,000 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Telaprevir 2.25 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Telithromycin 800 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Terbinafine 250 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Thioridazine 50 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Ticagrelor 90–180 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Ticlopidine 300 mg/d 75 (1) 88 (1.17) 113 (1.5) 86 (1.15) 168 (2.24) 214 (2.84)
Valproate 400–800 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Verapamil 240–480 mg/d 45 (0.6) 54 (0.72) 75 (1) 86 (1.15) 137 (1.83) 212 (2.83)
Voriconazole 400–800 mg/d 100 (1.21) 104 (1.38) 128 (1.71) 140 (1.86) 179 (2.38) 214 (2.85)
Notes: Clopidogrel adjusted dose in mg for clopidogrel dose of 75 mg = (interacting drug aUCXM*/aUCeM) ×75 mg. The values shown in bold refer to the dose, and the values 
in brackets refer to interacting aUC values. list of CYP2C19 inhibitors and inducers. aUC ratio calculation was adopted from Castellan et al.13 aUC consists of the area 
under the substrate concentration in blood or plasma over the dosing interval at steady state; aUCeM is the aUC of the substrate given alone in “extensive metabolizers”; 
aUCXM is the AUC of the substrate given alone in patients with any other phenotype (ultra-extensive metabolizer to poor metabolizer) as defined by the genotype of the 
major CYP2C19 involved in the substrate metabolism; aUCXM* is the aUC of the substrate given with an inhibitor or an inducer. Data from Castellan et al.13
Abbreviations: aUC, area under the curve; d, day.
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Figure 1 Clinical decision model algorithm for pharmacogenetic testing.
Abbreviation: aDRs, adverse reactions.
known as intermediate metabolizers) a lower drug metabolite 
level is expected, and consequently a higher clopidogrel 
dose is respectively indicated. A much higher dose is indi-
cated if the patient genotype is homozygous *2, or *3, or 
includes *3 and *2 in combination (which are known as 
poor metabolizers).11
Discussion
Pharmacogenetics and drug interactions share a partner-
ship in predicting patients’ resistance or sensitivity to drugs 
related effects. Thus, understanding the synergistic/additive/
antagonistic/subtractive effects of gene polymorphisms and 
drug interactions provides better patient care. Clopidogrel 
remains the thienopyridine drug with the most approved 
indications for use. CYP2C19 genetic mutations and drug 
interaction-mediated inhibition/induction cause reduction/
enhancement in activity of the enzyme, providing mutually 
corroborating scientific evidence for the interpretation of 
clinical consequences. Genetic variation in CYP2C19 has 
shown to affect plasma levels/effect of active metabolite of 
clopidogrel and therefore clopidogrel dosing, and patients 
have revealed different CYP2C19 gene polymorphisms; 
approximately, 5%–30% of patients are ultra-metabolizers, 
18%–45% are intermediate metabolizers, 2%–15% are poor 
metabolizers, as compared to 35%–50% of patients who are 
extensive metabolizers.14,15 Thus, dose adjustment would be 
required for almost more than 50% of patients.
To adjust clopidogrel dose and get the desired response in 
patients with loss of functional CYP2C19 allele, one option 
is to double the dose: the loading dose can be increased from 
300 to 600 mg, and the maintenance dose from 75 to 150 mg. 
The benefit has been evident in several studies,16–24 whereas 
contradictory results have been shown in other studies.25,26 
Another option is to switch from clopidogrel to a different 
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P2Y12 antagonist. Several agents, such as prasugrel, ticagre-
lor, elinogrel, and cangrelor, have been approved for this pur-
pose. Although the new drugs share a similar molecule or same 
mechanism of action to that of clopidogrel, and do not require 
CYP2C19 to biotransform into the active agent, patients have 
shown to be more prone to bleeding complications.27–29 The 
study provides an accurate dosing of clopidogrel as an alter-
native. Considering alternative dosing of clopidogrel, dose 
adjustment has to be accurately computed as shown in the 
study results; however, a major limitation is that clopidogrel 
is only available in 75 mg and 300 mg dosage strengths. Addi-
tionally, clopidogrel tablets are available as pills that cannot 
be split. Hence, if the patient requires a dose lower than 75 
mg, clinician should refer to a clopidogrel substitute.
When patients are extremely sensitive or resistant to 
clopidogrel effects at normal doses, the clinician should 
verify if the physical product is genuine if possible, exclude 
drug–drug interactions and then search for genetic varia-
tion in CYP2C19 metabolism as the underlying cause. The 
availability of such an alternative is integral to the process 
of integrating the use of the genetic biomarker into clinical 
decision-making, offering solutions to nonresponders or 
under-responders to therapy as well as to patients experienc-
ing side effects from the drug.
Conclusion
In conclusion, the study integrates clopidogrel–drug interac-
tion and pharmacogenetic studies in a clinical algorithm and 
provides an accurate dosing recommendation of clopidogrel. 
The implementation of such pharmacogenetic–drug interac-
tion approach has the potential to maximize the benefit of 
clopidogrel pharmacological therapy and to refine the choice 
of pharmacological agent that may be administered along 
with clopidogrel in patients on polypharmacy. Clinicians 
would be able to personalize treatment to enhance efficacy 
and/or limit toxicity.
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